Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines

doi:10.21203/rs.3.rs-2253092/v1

Download PDF

Research Article

Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines

https://doi.org/10.21203/rs.3.rs-2253092/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Purpose

NKG2A, an inhibitory receptor expressed on NK cells and T cells, leads to immune evasion by binding to HLA-E expressed on cancer cells. Here, we investigated the relationship between HLA-E surface expression on head and neck squamous cell carcinoma (HNSCC) cell lines and the efficacy of monalizumab, an NKG2A inhibitor, in promoting NK cell activity.

Methods

Six HNSCC cell lines were used as target cells. After exposure to IFN- γ, HLA-E surface expression on HNSCC cell lines was measured by flow cytometry. Peripheral blood mononuclear cells (PBMCs) from healthy donors and isolated NK cells were used as effector cells. NK cells were stimulated by treatment with IL-2 and IL-15 for 5 days, and NK cell-induced cytotoxicity was analyzed by CD107a degranulation and ⁵¹Cr release assays.

Results

We confirmed that HLA-E expression was increased by IFN-γ secreted by NK cells and that HLA-E expression was different for each cell line upon exposure to IFN-γ. Cell lines with high HLA-E expression showed stronger inhibition of NK cell cytotoxicity, and efficacy of monalizumab was high. Combination with cetuximb increased the efficacy of monalizumab. In addition, stimulation of isolated NK cells with IL-2 and IL-15 increased the efficacy of monalizumab, even in the HLA-E low groups.

Conclusion

Monalizumab efficacy was correlated with HLA-E surface expression and was enhanced when NK cell activity was increased by cetuximab or cytokines. These results suggest that monalizumab may be potent against HLA-E-positive tumors and that monalizumab efficacy could be improved by promoting NK cell activity.

monalizumab

head and neck squamous carcinoma

NKG2A/HLA-E axis

natural killer cells

NK cell stimulation

Patients with head and neck squamous carcinoma (HNSCC) have a poor prognosis (Johnson, Burtness, et al. 2020). Although therapies that modulate immune checkpoint molecules on T cells, such as programmed death protein-1 and programmed death ligand-1, show promising clinical responses for some cancer types (Herbst, Soria, et al. 2014, Powles, Eder, et al. 2014), the response rate to T-cell-based immunotherapy is generally low (Chen, Li, et al. 2018, Gotwals, Cameron, et al. 2017). Therefore, research focusing on other types of immune cells or immune checkpoint molecules is needed to develop new treatment strategies.

Natural killer (NK) cells not only directly eliminate tumor cells but also modulate adaptive immunity by releasing large amounts of cytokines such as interferon (IFN)-γ (Lee, Park, et al. 2017, Liu, Galat, et al. 2021). NK cells highly infiltrate into the tumor microenvironment (TME) of HNSCC (Charap, Enokida, et al. 2020, Mandal, Şenbabaoğlu, et al. 2016). However, tumor cells often show resistance to NK cells (Elmusrati, Wang, et al. 2021, Sordo-Bahamonde, Vitale, et al. 2020). Thus, cytokines such as interleukin (IL)-2 and IL-15 are used to enhance NK cell activity (Croxatto, Martini, et al. 2017, Koehl, Brehm, et al. 2013, Lehmann, Zeis, et al. 2001, Miller, Soignier, et al. 2005, Rautela and Huntington 2017) by modulating multiple inhibitory receptors on tumor cells (Paul and Lal 2017, Sentman, Barber, et al. 2006).

NKG2A, which dimerizes with CD94, is an inhibitory receptor expressed on NK cells and T cells that binds to HLA-E, a non-classical HLA class I molecule containing leader peptides of other HLA class I molecules (Iwaszko and Bogunia-Kubik 2011, Leibson 1998). Although HLA-E expression is often weak or absent on the cell surface of tumor cells, it is increased by IFN-γ from immune cells and protects against NK cell-induced lysis (Lo Monaco, Tremante, et al. 2011, Nguyen, Beziat, et al. 2009). Levels of HLA-E can increase within the TME due to antitumor responses, and the overexpression of HLA-E in several types of solid tumors is associated with poor prognosis (Benevolo, Mottolese, et al. 2011, de Kruijf, Sajet, et al. 2010, Gooden, Lampen, et al. 2011, Morinaga, Iwatsuki, et al. 2022). HLA-E plays a more predominant role in inhibiting NK cells than other HLA class I molecules (Sheffer, Lowry, et al. 2021) and also inhibits antibody-dependent cellular cytotoxicity (ADCC) (Ehlers, Beelen, et al. 2021, Levy, Sycz, et al. 2009, Ward, Bonaparte, et al. 2004). Several studies show that NKG2A blockade promotes the antitumor immunity of T cells and NK cells (André, Denis, et al. 2018, Ducoin, Oger, et al. 2022, Kamiya, Seow, et al. 2019, Ruggeri, Urbani, et al. 2016, Zaghi, Calvi, et al. 2019). Monalizumab, a novel IgG4 monoclonal antibody (mAb) targeting NKG2A, was recently developed (van Hall, André, et al. 2019). A preclinical study shows that monalizumab inhibits tumor progression by increasing NK cell and T cell activity, and clinical trials of monalizumab in combination with cetuximab are ongoing (André, Denis, et al. 2018, Cohen, Bauman, et al. 2020, Galot, Le Tourneau, et al. 2021, Herbst, Majem, et al. 2022, Salomé, Sfakianos, et al. 2022). However, factors predicting tumor response to monalizumab are not yet understood. In particular, it is unclear whether the level of HLA-E expression on tumor cells predicts response to monalizumab therapy.

The objective of this study was to evaluate the association between HLA-E surface expression on HNSCC cell lines and the efficacy of monalizumab on NK cells. We also investigated the correlation between NK cell activity and monalizumab efficacy after stimulation of NK cells by cytokines ex vivo.

Cell lines and cell culture

The human HNSCC cell lines SNU-1041, SNU-1066, SNU-1076 (purchased from the Korean Cell Line Bank, Seoul, Korea) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium, and Detroit-562 and FaDu (purchased from the American Type Culture Collection, Manassas, Virginia, USA) were cultured in Minimum Essential Media containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Recombinant human IFN-γ (R&D Systems, Minneapolis, MN, USA) was used to increase HLA-E surface expression.

Establishment of β2M KO SNU-1041 cells by CRISPR

Guide RNA, scrambled control, and GFP-puro donor in beta 2 microglobulin (β2M) Human Gene Knockout CRISPR Kit (ORIGENE, Rockville, MD, USA) was used to establish SNU-1041 MHC-I knockout (KO) cells. Lipofectamine and PLUS™ reagent (Invitrogen, Carlsbad, CA, USA) were used as transfection reagents, and transfection was performed according to the manufacturer’s instructions. Forty-eight hours after transfection, one-tenth of cells were split and grown again for 3 days, which was repeated for 3 weeks. β2M KO SNU-1041 cells were selected by puromycin (2 µg/ml), and non-expression of MHC-I was verified by flow cytometry.

Preparation of peripheral blood NK cells, NK cells isolated from peripheral blood mononuclear cells, and NK cell conditioned medium

Using Ficoll density gradient sedimentation, peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated using leukoreduction system chambers. PBMCs were activated in RPMI 1640 medium supplemented with 10% FBS and 1 ng/ml rhIL-15 (PeproTech, Rocky Hill, NJ, USA) for 5 days.

For the ⁵¹chromium (Cr) release assay and preparation of NK cell conditioned medium (CdM), NK cells were isolated from PBMCs using MACS columns and an NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Purified NK cells were cultured in NK MACS® Medium (Miltenyi Biotec) supplemented with 10% FBS, 500 IU/ml rhIL-2, and 10 ng rhIL-15. The purity of isolated NK cells was confirmed by flow cytometry. Purified NK cells were cultured in RPMI with 500 IU/ml rhIL-2 for 3 days to generate CdM. Cell culture supernatants were harvested by centrifugation and passed through a 0.45-µm Acrodisc syringe filter (Pall Corporation, Port Washington, NY, USA). IFN-γ mAb (NIB42; Thermo Fisher Scientific, Waltham, MA, USA) was used to neutralize IFN-γ in CdM.

Reagents and antibodies

To evaluate the efficacy of monalizumab to promote NK cell activity and ADCC, monalizumab and cetuximab were used. Monalizumab (purchased from Creative Biolabs, Shirley, NY, USA) is a humanized IgG4 mAb that targets NKG2A. Cetuximab is a chimeric IgG1 mAb targeting EGFR that induces ADCC.

Cell surface staining was performed using the following fluorescently labeled mAbs: isotype control-PE (MOPC-2, RRID:AB_396091), anti-HLA-E-PE (3D12, RRID:AB_2869949) (eBioscience, San Diego, CA, USA), anti-CD107a-PE (H4A3, RRID:AB_396135), CD16-FITC (3G8 RRID: AB_395806, BD Biosciences, San Jose, CA, USA), anti-CD3-eFlour450 (17A2. AB_1272193, Invitrogen), anti-CD56-PE-Vio770 (REA196, RRID:AB_2726091), and anti-NKG2A-APC (REA110, RRID:AB_2726447, Miltenyi Biotec). To exclude dead cells, eFluor 506 (#65-0866-14, Invitrogen) staining was performed. Golgi-Stop (#554724, BD Biosciences) was used in the CD107a degranulation assay as a protein transport inhibitor.

Analysis of cell surface protein expression using flow cytometry

Cell surface expression of HLA-E was measured by flow cytometry. Cells were incubated with or without 10 ng/ml IFN-γ for 24 hours and stained with fluorochrome-conjugated HLA-E antibody or isotype control for 20 min at 4°C. FACS Calibur (BD Biosciences) was used for data acquisition, and data were analyzed using FlowJo software (LCC, Ashland, OR, USA). mAb staining was measured as geometric mean fluorescence intensity (gMFI). We defined the difference between control and HLA-E-stained cancer cell lines as delta (Δ)gMFI.

CD107a degranulation assay

CD107a degranulation assay was performed using PBMCs or isolated NK cells from healthy donors with an effector-to-target (E:T) ratio of 1:1 using a previously described method (Park, Kim, et al. 2020). PBMCs (2 × 10⁵) or isolated NK cells were incubated with HNSCC cells for 1 hour at 37°C in U-bottom 96-well plates. Next, GolgiStop solution was added followed by incubation for 3 hours. All cells were transferred to a FACS tube, washed with FACS buffer, and stained with fluorescently labeled mAbs. Data were acquired and analyzed using a FACS Canto II (BD Biosciences) and FlowJo software.

⁵¹Cr release assay

⁵¹Cr release assay methodology is described in our previous study (Park, Ahn, et al. 2019). Target cells were labeled with 50 µCi for 1 hour at 37°C, and then 2.5 × 10⁵ cells were washed three times with growth media. Target cells were cultured with 10 µg/ml of the indicated antibodies, seeded at 5 × 10³ cells/well into U-bottom 96-well plates, and co-incubated with effector cells at a 10:1 E:T ratio for 4 hours at 37°C. Following co-culture, 75 µl supernatant from each well was transferred to 96-well PP 1.2-ml cluster tubes for gamma counting. To calculate radioactivity, a WIZARD2 Automatic Gamma Counter (PerkinElmer, Waltham, MA, USA) was used.

Statistical analysis

GraphPad Prism v7.0 (GraphPad Software, San Diego, CA, USA) was used to analyze data, which is reported as mean ± standard deviation (SD). Two-tailed paired Student’s t-tests were used to compare groups, and a two-sided P < 0.05 was considered statistically significant.

Surface expression of HLA-E in HNSCC cell lines

We measured the surface expression of HLA-E in HNSCC cell lines using flow cytometry. In normal conditions, all cell lines showed low HLA-E surface expression except for MHC-I KO cells. However, when IFN-γ was added, an increase in HLA-E expression was observed in all cell lines (Fig. 1A). Depending on the HLA-E expression level after IFN-γ treatment, cell lines with a change in mean fluorescence intensity (ΔMFI) ≥ 20 were classified into the HLA-E high group (SNU-1041, SNU-1066, and FaDu), whereas cell lines with ΔMFI < 20 were classified into the HLA-E negative or low group (SNU-1041 MHC-I KO, SNU-1076, and Detroit-562). There were no significant correlations between the HLA-E mRNA expression or genotype of each cell line and its level of HLA-E surface expression (Supplementary Fig. S1).

To confirm that HLA-E surface expression was increased due to IFN-γ secreted from NK cells, we prepared NK cell CdM. When SNU-1041 cells were cultured in CdM, the surface expression of HLA-E increased to a level similar to that following IFN-γ treatment, whereas neutralization with IFN-γ mAb attenuated this increase (Fig. 1B).

Correlation between HLA-E surface expression in HNSCC cell lines and monalizumab efficacy

To investigate the correlation between HLA-E surface expression in HNSCC cell lines and monalizumab efficacy, we measured the cytotoxicity of primary NK cells in PBMCs by CD107a degranulation assay. PBMCs were activated with a low concentration of IL-15 (1 ng/ml) for 3 days, and NK cells were identified by flow cytometry (Supplementary Fig. S2). There were no statistical significant effects of monalizumab among HNSCC cell lines in the negative or low HLA-E group either under control conditions or after IFN-γ treatment (Fig. 2A). However, among HNSCC cell lines in the HLA-E high group, monalizumab showed significant effects, with even larger effects when monalizumab was combined with cetuximab (Fig. 2B).

The level of HLA-E surface expression was correlated with the degree of inhibition of cytotoxic NK cells, including ADCC induced by cetuximab (Fig. 3A, B). In addition, the recovery of cytotoxic NK cells by monalizumab was correlated with HLA-E surface expression (Fig. 3C). Taken together, these results suggest that HLA-E surface expression in HNSCC cell lines predicts the efficacy of monalizumab in promoting NK cell activity.

Ex vivo stimulation of NK cells increases the efficacy of monalizumab

To measure the efficacy of monalizumab upon stimulation of NK cells with a cytokine, we performed a CD107a degranulation assay after isolating NK cells from PBMCs. When the assay was performed with NK cells incubated in growth medium for 1 day, the effect of monalizumab was not significant in any HNSCC cell line, even when combined with cetuximab (Supplementary Fig. S3). By contrast, after stimulation with IL-2 (500 IU/ml) and IL-15 (10 ng/ml) for 5 days, effects of monalizumab alone and monalizumab combined with cetuximab were observed for SNU-1041 cells with high HLA-E surface expression as well as SNU-1076 cells with negative or low HLA-E surface expression (Fig. 4A). The effect of monalizumab alone was comparable to that of cetuximab in SNU-1076 cells and was higher than that of cetuximab in SNU-1041 cells.

We also performed a ⁵¹Cr release assay to confirm whether ex vivo stimulation with a cytokine improves the effect of monalizumab. As with the CD107a degranulation assay results, effects of monalizumab alone and monalizumab in combination with cetuximab were observed in all HNSCC cell lines including those in the HLA-E negative or low group, although larger effects were observed in the HLA-E high group (Fig. 4B, C). These results suggest that stimulation of NK cells by IL-2 and IL-15 enhances the efficacy of monalizumab.

We found a correlation between HLA-E surface expression on HNSCC cell lines and monalizumab efficacy in promoting NK cell activity. We also showed that combination of cetuximab and stimulation of NK cells with IL-2 and IL-15 improved the efficacy of monalizumab, even in cell lines with low HLA-E surface expression (Fig. 5). These findings suggest that the antitumor effect of monalizumab is stronger in tumors with higher HLA-E expression and depends on NK cell activity.

By measuring levels of HLA-E surface expression on HNSCC cell lines, we showed that HLA-E expression was increased by IFN-γ secreted from NK cells. The surface expression of HLA-E requires binding to the MHC-I leader sequence, and HLA-E surface expression and affinity for NKG2A vary depending on the type of leader peptide that is bound (Battin, Kaufmann, et al. 2022, Matsunami, Miyagawa, et al. 2002). Antibodies that bind HLA-E leader peptide complexes enhance NK cell cytotoxicity (Li, Brackenridge, et al. 2022). HLA-E surface expression is also affected by tapasin, TAP, and β₂M, which are involved in movement to the cell surface (Braud, Allan, et al. 1998, Lee, Goodlett, et al. 1998, Lo Monaco, Sibilio, et al. 2008). We found that the surface expression of HLA-E in HNSCC cell lines increased upon exposure to IFN-γ, consistent with previous studies (Derré, Corvaisier, et al. 2006, Nguyen, Beziat, et al. 2009), likely due to activation of the STAT-1 pathway by IFN-γ (Lee and Benveniste 1996, Zhou 2009). As HLA-E expression in the TME is also increased by IFN-γ, expression of IFN-γ and STAT-1 pathway-related genes in the TME may also be affected. Furthermore, HLA-E surface expression is high in acute leukemia patients with the genotype HLA-E*01:03 (Lauterbach, Wieten, et al. 2015, Xu, Wieten, et al. 2019), suggesting that the genotype of HLA-E could affect HLA-E surface expression. However, in the present study, neither the surface expression of HLA-E nor the level of HLA-E mRNA was significantly associated with genotype. Together, these findings suggest that the surface expression of HLA-E is affected by complex interactions among multiple factors, which requires clarification through future studies.

Using CD107a degranulation assay, we observed correlations between HLA-E expression and monalizumab efficacy, with stronger correlations observed when monalizumab was combined with cetuximab. The higher efficacy of monalizumab, when used in combination with cetuximab, may be due to an increase in NK cell activity through the CD16 receptor, which also mediates ADCC (Capuano, Pighi, et al. 2021). Monalizumab has been demonstrated to have potency in combination with other treatments (van Hall, André, et al. 2019), and clinical trials of monalizumab combination therapies are ongoing (NCT02643550, NCT02671435, NCT05221840). Our results suggest that HLA-E surface expression is a tumor biomarker for monalizumab efficacy and that the use of monalizumab in combination with other cancer therapies that promote NK cell or T cell activity could be more effective. INTERLINK-1 phase 3 trial (NCT04590963) which compared cetuximab with/without monalizumab in HNSCC had terminated because of futility issue. We speculate that better outcomes could be obtained when they apply molecular enrichment based on HLA-E-positivity in patient selection.

In unstimulated NK cells, even the combination of monalizumab and cetuximab did not show efficacy, whereas stimulation of NK cells with IL-2 and IL-15 increased the efficacy of monalizumab in both CD107a degranulation and ⁵¹Cr release assays, even within the HLA-E low group. In vitro stimulation of NK cells with IL-2 and/or IL-15 increases NK cell-activating receptors and NK cell cytotoxicity (Croxatto, Martini, et al. 2017, Horng, Bezbradica, et al. 2007, Lehmann, Zeis, et al. 2001, Sanchez-Correa, Bergua, et al. 2017, Wang, Frank, et al. 2000). Also, in vitro stimulation increases the ratio of NKG2A⁺ NK cells (André, Denis, et al. 2018, Hromadnikova, Pirkova, et al. 2013), and NKG2A⁺ NK cells may induce more cytotoxicity (Mahaweni, Ehlers, et al. 2018). Taken together, these findings suggest that the efficacy of monalizumab increases when NK cell activity is promoted by cytokine treatment and that NK cell activity in the TME is important. In addition, considering that adoptive NK cell transfer is an attractive therapeutic candidate for solid tumors and that NKG2A is an interfering factor (Cichocki and Miller 2019), these findings imply that adoptive NK cell therapy may exert greater antitumor activity when combined with monalizumab after ex vivo stimulation.

Our study has several limitations. As our study employed only in vitro experiments, verification of our results using in vivo experiments is required. Our experiment did not take into account the infiltration of NK cells into the TME or interactions with other immune cells that may affect the efficacy of monalizumab. Furthermore, it is necessary to determine the major factors that affect HLA-E surface expression in vivo. However, this study is meaningful in that it firstly identifies a potential biomarker and effective therapeutic strategy involving monalizumab.

In conclusion, our study reveals that HLA-E surface expression on HNSCC cell lines is correlated with monalizumab efficacy and that increasing NK cell activity by combined treatment with cetuximab or cytokines enhances the efficacy of monalizumab. Our findings suggest that monalizumab has potency against tumors with higher HLA-E surface expression and that the efficacy of monalizumab is improved when NK cell activity is increased by other treatments.

Funding: This study was supported by a grant from the Korea Health Industry Development Institute (KHIDI) [grant number: HI14C1277] and the National R&D Program for Cancer Control [grant number: HA16C0015], funded by Ministry of Health and Welfare (MHW), Republic of Korea.

Competing Interests: None declared

Author Contributions: Conception and design: JL and BK. Development of methodology: JL, BK, H-RP, J-EP, SK and TMK. Acquisition of data (eg, provided cells and provided facilities, etc.): JL, H-RP, J-EP and SK. Analysis and interpretation of data: JL, BK, SK and TMK, Study supervision: BK, SK, MK, TMK, D-WK and DSH, Writing, review and/or revision of the manuscript: all authors

Data Availability: Data are available upon reasonable request. Contact email: bhumsuk@ snu. ac. kr.

André P, Denis C, et al. (2018) Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell.175(7):1731-43.e13. 10.1016/j.cell.2018.10.014
Battin C, Kaufmann G, et al. (2022) NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E. Immunology.166(4):507-21. 10.1111/imm.13515
Benevolo M, Mottolese M, et al. (2011) High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med.9:184. 10.1186/1479-5876-9-184
Braud VM, Allan DS, et al. (1998) TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol.8(1):1-10. 10.1016/s0960-9822(98)70014-4
Capuano C, Pighi C, et al. (2021) Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. Cancers (Basel).13(10). 10.3390/cancers13102500
Charap AJ, Enokida T, et al. (2020) Landscape of natural killer cell activity in head and neck squamous cell carcinoma. J Immunother Cancer.8(2). 10.1136/jitc-2020-001523
Chen Q, Li T, et al. (2018) Drug response to PD-1/PD-L1 blockade: based on biomarkers. Onco Targets Ther.11:4673-83. 10.2147/ott.S168313
Cichocki F, Miller JS. (2019) Setting traps for NKG2A gives NK cell immunotherapy a fighting chance. J Clin Invest.129(5):1839-41. 10.1172/jci128480
Cohen RB, Bauman JR, et al. (2020) Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors. Journal of Clinical Oncology.38(15_suppl):6516-. 10.1200/JCO.2020.38.15_suppl.6516
Croxatto D, Martini S, et al. (2017) IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid. Oncoimmunology.6(4):e1293210. 10.1080/2162402x.2017.1293210
de Kruijf EM, Sajet A, et al. (2010) HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol.185(12):7452-9. 10.4049/jimmunol.1002629
Derré L, Corvaisier M, et al. (2006) Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol.177(5):3100-7. 10.4049/jimmunol.177.5.3100
Ducoin K, Oger R, et al. (2022) Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. Oncoimmunology.11(1):2046931. 10.1080/2162402x.2022.2046931
Ehlers FAI, Beelen NA, et al. (2021) ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response. Cancers (Basel).13(13). 10.3390/cancers13133232
Elmusrati A, Wang J, et al. (2021) Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci.13(1):24. 10.1038/s41368-021-00131-7
Galot R, Le Tourneau C, et al. (2021) A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. Eur J Cancer.158:17-26. 10.1016/j.ejca.2021.09.003
Gooden M, Lampen M, et al. (2011) HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A.108(26):10656-61. 10.1073/pnas.1100354108
Gotwals P, Cameron S, et al. (2017) Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer.17(5):286-301. 10.1038/nrc.2017.17
Herbst RS, Soria J-C, et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature.515(7528):563-7. 10.1038/nature14011
Herbst RS, Majem M, et al. (2022) COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol.Jco2200227. 10.1200/jco.22.00227
Horng T, Bezbradica JS, et al. (2007) NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol.8(12):1345-52. 10.1038/ni1524
Hromadnikova I, Pirkova P, et al. (2013) Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors. Mediators Inflamm.2013:405295. 10.1155/2013/405295
Iwaszko M, Bogunia-Kubik K. (2011) Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch Immunol Ther Exp (Warsz).59(5):353-67. 10.1007/s00005-011-0137-y
Johnson DE, Burtness B, et al. (2020) Head and neck squamous cell carcinoma. Nature Reviews Disease Primers.6(1):92. 10.1038/s41572-020-00224-3
Kamiya T, Seow SV, et al. (2019) Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest.129(5):2094-106. 10.1172/jci123955
Koehl U, Brehm C, et al. (2013) Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol.3:118. 10.3389/fonc.2013.00118
Lauterbach N, Wieten L, et al. (2015) Peptide-induced HLA-E expression in human PBMCs is dependent on peptide sequence and the HLA-E genotype. Tissue Antigens.85(4):242-51. 10.1111/tan.12525
Lee J, Park KH, et al. (2017) Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer. Oncotarget.8(41):70431-40. 10.18632/oncotarget.19712
Lee N, Goodlett DR, et al. (1998) HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol.160(10):4951-60.
Lee YJ, Benveniste EN. (1996) Stat1 alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes. J Immunol.157(4):1559-68.
Lehmann C, Zeis M, et al. (2001) Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br J Haematol.114(3):660-5. 10.1046/j.1365-2141.2001.02995.x
Leibson PJ. (1998) Cytotoxic lymphocyte recognition of HLA-E: utilizing a nonclassical window to peer into classical MHC. Immunity.9(3):289-94. 10.1016/s1074-7613(00)80611-1
Levy EM, Sycz G, et al. (2009) Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun.15(2):91-100. 10.1177/1753425908101404
Li D, Brackenridge S, et al. (2022) Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. Communications Biology.5(1):271. 10.1038/s42003-022-03183-5
Liu S, Galat V, et al. (2021) NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol.14(1):7. 10.1186/s13045-020-01014-w
Lo Monaco E, Sibilio L, et al. (2008) HLA-E: Strong Association with β<sub>2</sub>-Microglobulin and Surface Expression in the Absence of HLA Class I Signal Sequence-Derived Peptides. The Journal of Immunology.181(8):5442. 10.4049/jimmunol.181.8.5442
Lo Monaco E, Tremante E, et al. (2011) Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia.13(9):822-30. 10.1593/neo.101684
Mahaweni NM, Ehlers FAI, et al. (2018) NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment. Front Immunol.9:1415. 10.3389/fimmu.2018.01415
Mandal R, Şenbabaoğlu Y, et al. (2016) The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight.1(17):e89829. 10.1172/jci.insight.89829
Matsunami K, Miyagawa S, et al. (2002) Modulation of the leader peptide sequence of the HLA-E gene up-regulates its expression and down-regulates natural killer cell-mediated swine endothelial cell lysis. Transplantation.73(10):1582-9. 10.1097/00007890-200205270-00010
Miller JS, Soignier Y, et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood.105(8):3051-7. 10.1182/blood-2004-07-2974
Morinaga T, Iwatsuki M, et al. (2022) Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer. Ann Surg Oncol.29(8):4951-60. 10.1245/s10434-022-11665-3
Nguyen S, Beziat V, et al. (2009) HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transplant.43(9):693-9. 10.1038/bmt.2008.380
Park HR, Ahn YO, et al. (2019) NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. Cytotherapy.21(6):603-11. 10.1016/j.jcyt.2019.03.312
Park J-E, Kim S-E, et al. (2020) Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. Journal for ImmunoTherapy of Cancer.8(2):e000873. 10.1136/jitc-2020-000873
Paul S, Lal G. (2017) The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front Immunol.8:1124. 10.3389/fimmu.2017.01124
Powles T, Eder JP, et al. (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature.515(7528):558-62. 10.1038/nature13904
Rautela J, Huntington ND. (2017) IL-15 signaling in NK cell cancer immunotherapy. Curr Opin Immunol.44:1-6. 10.1016/j.coi.2016.10.004
Ruggeri L, Urbani E, et al. (2016) Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica.101(5):626-33. 10.3324/haematol.2015.135301
Salomé B, Sfakianos JP, et al. (2022) NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell.40(9):1027-43.e9. 10.1016/j.ccell.2022.08.005
Sanchez-Correa B, Bergua JM, et al. (2017) In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients. Front Immunol.8:931. 10.3389/fimmu.2017.00931
Sentman CL, Barber MA, et al. (2006) NK cell receptors as tools in cancer immunotherapy. Adv Cancer Res.95:249-92. 10.1016/s0065-230x(06)95007-6
Sheffer M, Lowry E, et al. (2021) Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nat Genet.53(8):1196-206. 10.1038/s41588-021-00889-w
Sordo-Bahamonde C, Vitale M, et al. (2020) Mechanisms of Resistance to NK Cell Immunotherapy. Cancers (Basel).12(4). 10.3390/cancers12040893
van Hall T, André P, et al. (2019) Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer.7(1):263. 10.1186/s40425-019-0761-3
Wang KS, Frank DA, et al. (2000) Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood.95(10):3183-90.
Ward JP, Bonaparte MI, et al. (2004) HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. Aids.18(13):1769-79. 10.1097/00002030-200409030-00005
Xu YP, Wieten L, et al. (2019) Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia. Leuk Lymphoma.60(1):208-15. 10.1080/10428194.2018.1474521
Zaghi E, Calvi M, et al. (2019) Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy. J Leukoc Biol.105(6):1243-51. 10.1002/jlb.Mr0718-300r
Zhou F. (2009) Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol.28(3-4):239-60. 10.1080/08830180902978120

No competing interests reported.

Supplementarymaterials.docx

Download PDF

Editorial decision: Major revision
05 Dec, 2022
Reviews received at journal
05 Dec, 2022
Reviewers agreed at journal
15 Nov, 2022
Reviewers invited by journal
11 Nov, 2022
Editor assigned by journal
10 Nov, 2022
Submission checks completed at journal
09 Nov, 2022
First submitted to journal
08 Nov, 2022

You are reading this latest preprint version

Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines

Status:

Version 1

Abstract

Purpose

Methods

Results

Conclusion

Figures

Introduction

Materials And Methods

Cell lines and cell culture

Establishment of β2M KO SNU-1041 cells by CRISPR

Preparation of peripheral blood NK cells, NK cells isolated from peripheral blood mononuclear cells, and NK cell conditioned medium

Reagents and antibodies

Analysis of cell surface protein expression using flow cytometry

CD107a degranulation assay

⁵¹Cr release assay

Statistical analysis

Results

Surface expression of HLA-E in HNSCC cell lines

Correlation between HLA-E surface expression in HNSCC cell lines and monalizumab efficacy

Ex vivo stimulation of NK cells increases the efficacy of monalizumab

Discussion

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1

Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines

Status:

Version 1

Abstract

Purpose

Methods

Results

Conclusion

Figures

Introduction

Materials And Methods

Cell lines and cell culture

Establishment of β2M KO SNU-1041 cells by CRISPR

Preparation of peripheral blood NK cells, NK cells isolated from peripheral blood mononuclear cells, and NK cell conditioned medium

Reagents and antibodies

Analysis of cell surface protein expression using flow cytometry

CD107a degranulation assay

51Cr release assay

Statistical analysis

Results

Surface expression of HLA-E in HNSCC cell lines

Correlation between HLA-E surface expression in HNSCC cell lines and monalizumab efficacy

Ex vivo stimulation of NK cells increases the efficacy of monalizumab

Discussion

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1

⁵¹Cr release assay